76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Compass Pathways Plc ADR
Closed
2.67 -3.26
Overview
Share price change
24h
Min
2.58
Max
2.76
Income | 25M -18M |
|---|---|
EPS | -0.419 |
Employees | 166 |
EBITDA | -8.5M -50M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +564.03% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | -152M 237M |
|---|---|
Previous open | 5.93 |
Previous close | 2.67 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Compass Pathways Plc ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Compass Pathways Plc ADR Forecast
Price Target
By TipRanks
564.03% upside
12 Months Forecast
Average 16.8 USD 564.03%
High 45 USD
Low 7 USD
Based on 10 Wall Street analysts offering 12 month price targets forCompass Pathways Plc ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
